STOCK TITAN

Iridex - IRIX STOCK NEWS

Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.

Iridex Corporation (IRIX) delivers innovative laser-based medical systems for ophthalmology, specializing in noninvasive treatments for glaucoma and retinal diseases. This news hub provides investors and healthcare professionals with timely updates on product developments, financial performance, and clinical advancements.

Access authoritative information about IRIX's proprietary MicroPulse technology, regulatory milestones, and global market initiatives. Our curated collection features earnings announcements, partnership updates, and clinical study results – all essential for tracking the company's position in medical device innovation.

Discover updates across key categories including new product clearances, international distribution expansions, and peer-reviewed research findings. Content is regularly updated to reflect IRIX's progress in enhancing ophthalmic care through advanced laser systems and procedural tools.

Bookmark this page for streamlined access to verified Iridex developments. Combine strategic business insights with technical expertise through our comprehensive news repository – your primary source for monitoring this medical technology leader's trajectory.

Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) is showcasing its innovative glaucoma treatment technologies at the 2022 American Academy of Ophthalmology annual meeting. The company introduces the Sweep Management Software for its Cyclo G6 Glaucoma Laser System, enhancing the precision of MicroPulse Transscleral Laser Therapy (TLT). This non-incisional treatment can reduce intraocular pressure by 25% to 45%. Iridex emphasizes its commitment to advancing glaucoma care through educational presentations and demonstrations at booth #5139.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
-
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, set for August 31, 2022, at 1:00 p.m. PT / 4:00 p.m. ET. During the virtual event, management will present the company's innovative ophthalmic laser-based medical products aimed at treating glaucoma and retinal diseases. A live webcast of the presentation will be available, with an archived version accessible on the Iridex website for further insights into their MicroPulse® technology and product offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
conferences
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported a 2% increase in total revenue to $13.8 million for Q2 2022. Despite a 3% decline in Cyclo G6 product revenue to $3.5 million, they sold 48 Glaucoma Laser Systems, slightly up from 47 the previous year. Operating expenses rose by 16% to $8.4 million, contributing to a net loss of $2.2 million or $0.14 per share. The company adjusted its full-year revenue guidance to $56-58 million, down from $57-59 million. Regulatory clearance in China positions them for potential growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.25%
Tags
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q2 2022 on August 15, 2022, after market hours. A conference call, led by the management team, is scheduled for 2:00 p.m. PT / 5:00 p.m. ET to discuss these results. Investors can participate by registering in advance or by accessing the live webcast on Iridex's website. Iridex is a leader in developing laser-based medical products for ophthalmology, focusing on treatments for glaucoma and retinal diseases, with a strong presence in the U.S. and over 100 countries worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) announced regulatory clearance from China's National Medical Products Administration to market its Cyclo G6® platform for glaucoma treatment. Set to launch in Q3 2022, the Cyclo G6 system, utilizing MicroPulse Transcleral Laser Therapy, aims to address the significant glaucoma issue in China, where an estimated 9.4 million adults suffer from Glaucomatous Optic Neuropathy. This clearance marks a pivotal opportunity for Iridex to expand awareness and adoption of its innovative solutions in a large market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported record first quarter revenue of $13.4 million, a 12% increase year-over-year. Key highlights include $3.5 million from Cyclo G6 products and $7.3 million from Retina products, boosted by the PASCAL acquisition. Operating expenses rose by 22% to $8.3 million, contributing to a net loss of $2.4 million or $0.15 per share. The company reiterated its full-year guidance, expecting $57 million to $59 million in total revenue and Cyclo G6 probe sales growth of 15% to 20%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced it will release its first quarter 2022 financial results after trading on May 12, 2022. A conference call with management will follow at 2:00 p.m. PT / 5:00 p.m. ET. Iridex is recognized for its innovative ophthalmic laser-based products targeting glaucoma and retinal diseases. The company utilizes proprietary MicroPulse® technology, offering effective treatments for various eye conditions, with products available in the U.S., Germany, and over 100 other countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences earnings
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) announced the appointment of Beverly Huss to its board of directors, effective March 17, 2022. The board size increased from five to six members to accommodate her role. Huss brings over 25 years of experience in the medical device industry, having held leadership roles at Pagonia Medical and Qool Therapeutics. She expressed her commitment to advancing Iridex’s laser-based treatments for glaucoma. Iridex specializes in developing innovative laser technologies for ophthalmic applications, including treatments for glaucoma and retinal diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
management
-
Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported a record fourth quarter revenue of $15.3 million, up 24% year-over-year, driven by strong demand in glaucoma and retina product lines. For the full year, revenue increased 48% to $53.9 million. Gross profit margins slightly declined to 39.3% in Q4, attributed to a higher mix of international system sales. Despite increased operating expenses of 43% to $8.4 million, the net loss narrowed to $2.4 million in Q4. Looking ahead, Iridex projects a revenue forecast of $57-$59 million for 2022, aiming for continued growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced its participation in the 34th Annual Roth Conference, scheduled for March 15, 2022, at 10:00 a.m. PT / 1:00 p.m. ET. The company specializes in innovative ophthalmic laser-based medical products for treating glaucoma and retinal diseases. A live and archived webcast of the presentation will be accessible on the company's website. Iridex is recognized for its MicroPulse® technology, which offers effective treatments for various sight-threatening eye conditions, with products available in over 100 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
Iridex

Nasdaq:IRIX

IRIX Rankings

IRIX Stock Data

16.97M
13.34M
20.67%
19.45%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW